Trifluperidol
Systematic (IUPAC) name | |
---|---|
1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
Identifiers | |
CAS Number | 749-13-3 |
ATC code | N05AD02 (WHO) |
PubChem | CID 5567 |
ChemSpider | 5366 |
UNII | R8869Q7R8I |
ChEMBL | CHEMBL15023 |
Chemical data | |
Formula | C22H23F4NO2 |
Molar mass | 409.417 g/mol |
| |
| |
(what is this?) (verify) |
Trifluperidol is a typical antipsychotic of the butyrophenone chemical class. It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects. It is used in the treatment of psychoses including mania and schizophrenia. It was discovered at Janssen Pharmaceutica in 1959.
Synthesis
References
- Gallant DM, Bishop MP, Timmons E, Steele CA, A controlled evaluation of Trifluperidol: a new potent psychopharmacologic agent, Curr Ther Res Clin Exp. 1963 Sep;27:463-71.
- Gallant DM, Bishop MP, Timmons E, Steele CA, Trifluperidol: a butyrophenone derivative, Am J Psychiatry. 1963 Nov;120:485-7.
|
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.